Nuclear Factor-κB Pathway-activating Gene Aberrancies in Primary Cutaneous Large B-cell Lymphoma, Leg Type

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2013 Jul 19

PMID 23863863

Citations 18

Authors

Lianne Koens

Willem H Zoutman

Passorn Ngarmlertsirichai

Grzegorz K Przybylski

Piotr Grabarczyk

Maarten H Vermeer

Rein Willemze

Patty M Jansen

Christian A Schmidt

Cornelis P Tensen

Affiliations

Soon will be listed here.

Citing Articles

Role of RNA Splicing Mutations in Diffuse Large B Cell Lymphoma.

Berta D, Girma M, Melku M, Adane T, Birke B, Yalew A Int J Gen Med. 2023; 16:2469-2480.

PMID: 37342407 PMC: 10278864. DOI: 10.2147/IJGM.S414106.

Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms-Updated Classification and New Concepts.

Kurz K, Ott M, Kalmbach S, Steinlein S, Kalla C, Horn H Cancers (Basel). 2023; 15(8).

PMID: 37190213 PMC: 10137297. DOI: 10.3390/cancers15082285.

Primary Cutaneous B-Cell Lymphomas with Large Cell Morphology: A Practical Review.

Ronchi A, Vitiello P, DAbbronzo G, Caccavale S, Argenziano G, Sica A Int J Mol Sci. 2023; 24(7).

PMID: 37047176 PMC: 10094092. DOI: 10.3390/ijms24076204.

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.

Wobser M, Schummer P, Appenzeller S, Kneitz H, Roth S, Goebeler M Cancers (Basel). 2022; 14(21).

PMID: 36358692 PMC: 9654082. DOI: 10.3390/cancers14215274.

Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment.

Zhang Y, LeWitt T, Louissaint Jr A, Guitart J, Zhou X, Choi J J Invest Dermatol. 2022; 143(2):189-196.

PMID: 36163302 PMC: 10260375. DOI: 10.1016/j.jid.2022.07.027.

References

Dal Porto J, Gauld S, Merrell K, Mills D, Pugh-Bernard A, Cambier J . B cell antigen receptor signaling 101. Mol Immunol. 2004; 41(6-7):599-613. DOI: 10.1016/j.molimm.2004.04.008. View

Yang Y, Shaffer 3rd A, Emre N, Ceribelli M, Zhang M, Wright G . Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012; 21(6):723-37. PMC: 4059833. DOI: 10.1016/j.ccr.2012.05.024. View

Chu Y, Vahl J, Kumar D, Heger K, Bertossi A, Wojtowicz E . B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood. 2010; 117(7):2227-36. DOI: 10.1182/blood-2010-09-306019. View

Sommer K, Guo B, Pomerantz J, Bandaranayake A, Moreno-Garcia M, Ovechkina Y . Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity. 2005; 23(6):561-74. DOI: 10.1016/j.immuni.2005.09.014. View

Ngo V, Young R, Schmitz R, Jhavar S, Xiao W, Lim K . Oncogenically active MYD88 mutations in human lymphoma. Nature. 2010; 470(7332):115-9. PMC: 5024568. DOI: 10.1038/nature09671. View

Compagno M, Lim W, Grunn A, Nandula S, Brahmachary M, Shen Q . Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459(7247):717-21. PMC: 2973325. DOI: 10.1038/nature07968. View

Ngo V, Davis R, Lamy L, Yu X, Zhao H, Lenz G . A loss-of-function RNA interference screen for molecular targets in cancer. Nature. 2006; 441(7089):106-10. DOI: 10.1038/nature04687. View

Lamason R, McCully R, Lew S, Pomerantz J . Oncogenic CARD11 mutations induce hyperactive signaling by disrupting autoinhibition by the PKC-responsive inhibitory domain. Biochemistry. 2010; 49(38):8240-50. PMC: 2943563. DOI: 10.1021/bi101052d. View

Hoefnagel J, Dijkman R, Basso K, Jansen P, Hallermann C, Willemze R . Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2004; 105(9):3671-8. DOI: 10.1182/blood-2004-04-1594. View

10.

Senff N, Noordijk E, Kim Y, Bagot M, Berti E, Cerroni L . European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008; 112(5):1600-9. DOI: 10.1182/blood-2008-04-152850. View

11.

Pham-Ledard A, Cappellen D, Martinez F, Vergier B, Beylot-Barry M, Merlio J . MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type. J Invest Dermatol. 2012; 132(8):2118-20. DOI: 10.1038/jid.2012.102. View

12.

Naylor T, Tang H, Ratsch B, Enns A, Loo A, Chen L . Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res. 2011; 71(7):2643-53. DOI: 10.1158/0008-5472.CAN-10-2525. View

13.

Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y . TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood. 2009; 114(12):2467-75. DOI: 10.1182/blood-2008-12-194852. View

14.

Davis R, Brown K, Siebenlist U, Staudt L . Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-74. PMC: 2193582. DOI: 10.1084/jem.194.12.1861. View